Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placeboPAP · people with pulmonary hypertension due to lung disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 61 participantsModerate